Sort   by:  
 Page size 
UnknownDerived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Not available
S-EPMC8875201 | biostudies-literature
UnknownComparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Not available
S-EPMC5885830 | biostudies-literature
UnknownThe Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Not available
S-EPMC11528202 | biostudies-literature
UnknownTumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
Not available
S-EPMC12480687 | biostudies-literature
Unknown<i>PFMG2025</i>-integrating genomic medicine into the national healthcare system in France.
Not available
S-EPMC11910791 | biostudies-literature
UnknownIdentification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Not available
S-EPMC4962376 | biostudies-literature
UnknownNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Not available
S-EPMC4630206 | biostudies-literature
UnknownLarge-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Not available
S-EPMC10942532 | biostudies-literature
UnknownGenome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.
Not available
S-EPMC12635163 | biostudies-literature
UnknownA case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Not available
S-EPMC7890067 | biostudies-literature
Sort   by:  
 Page size